AZD 9574
Alternative Names: AZD-9574Latest Information Update: 29 Jul 2022
At a glance
- Originator AstraZeneca
- Class Antineoplastics; Small molecules
- Mechanism of Action Poly(ADP-ribose) polymerase-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 24 Jun 2022 Phase-I/II clinical trials in Solid tumours (Combination therapy, Late-stage disease, Second-line therapy or greater, Metastatic disease, Recurrent) in USA, Australia (PO) (NCT05417594)
- 24 Jun 2022 Phase-I/II clinical trials in Solid tumours (Monotherapy, Late-stage disease, Second-line therapy or greater, Recurrent, Metastatic disease) in USA, Australia (PO) (NCT05417594)
- 14 Jun 2022 AstraZeneca plans a phase I/II CERTIS1 trial for Solid tumors (Combination therapy, Late-stage disease, Recurrent, Second-line therapy or greater) in USA, Australia, Spain, Sweden, United Kingdom, Germany and South Korea in June 2022 (NCT05417594) (D8410C00001) (EudraCT 2021-006227-17)